Home|Journals|Articles by Year|Audio Abstracts

Original Article

J App Pharm Sci. 2018; 8(12): 157-164

In silico evaluation of Benzo (f) chromen-3-one as a potential inhibitor of NF-κB: A Key regulatory molecule in Inflammation-mediated pathogenesis of Diabetes, Alzheimer’s and Cancer

Sandeep Kumar Gandham, Venkata Ramaiah Chintha, Rajendra Wudayagiri.


This study is aimed to evaluate the impact of Benzo (f) chromen-3-one, a plant compound present in Artemisia vulgaris, which was retrieved from pubchem database, as a NF-κB inhibitor, a key regulator found to be chronically activated in various ailments, such as Cancer, Diabetes, Rheumatoid Arthritis, Alzheimers and Inflammation etc. Molecular properties of the compound were analysed using Molinspiration and Swiss ADME servers. Molecular docking studies were performed followed by pathway analysis using STRING and KEGG databases. Docking results indicate grater binding affinity of the compound with NF-κB molecule. Molecular properties of the compound are in agreement with the Lipinski rule of five and also possess good pharmacological properties. Pathway analyses clarify the connecting link between various ailments in inflammation induced disease pathogenesis. Our computational analysis rationalizes the inhibitory ability of naturally occurring plant compound to alter the NF-κB signalling pathway. Docking studies substantiates the hypothesis that Benzo (f) chromen-3-one has significant potential to inhibit the NF-κB.

Key words: Benzo (f) chromen-3-one, NF-κB, Molecular docking, inflammation.

Full-text options

Share this Article

Online Article Submission
• ejmanager.com

ejPort - eJManager.com
Review(er)s Central
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.